This clinical trial is focused on studying schizophrenia, a mental health condition that affects how a person thinks, feels, and behaves. The trial will use a medication called emraclidine, also known by its code name CVL-231. The purpose of the study is to evaluate the long-term safety and tolerability of this medication in adults who have schizophrenia.

Participants in the study will take emraclidine in the form of a tablet, which is taken orally. The study will last for 52 weeks, during which time participants will be monitored to see how well they tolerate the medication and to check for any side effects. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of emraclidine.

Throughout the study, participants will have regular visits with the research team to assess their health and any changes in their condition. These visits will include physical and neurological examinations, as well as assessments of vital signs, body weight, and other health parameters. The study aims to provide valuable information about the long-term use of emraclidine for treating schizophrenia, helping to determine its safety and effectiveness for future use.